Annual report pursuant to Section 13 and 15(d)

Income Taxes (Tables)

v3.22.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of deferred tax assets and liabilities
(in thousands)   2021     2020  
Deferred tax assets:            
Net operating losses carry forward   $ 36,405     $ 33,955  
Share-based compensation     1,213       1,689  
Research and development/orphan drug credits     14,536       12,638  
Intangibles     10,426       7,873  
Others     19       19  
Less: valuation allowance     (62,599 )     (56,174 )
Deferred tax assets, net   $
-
    $
-
 

 

Schedule of difference between income tax provision and U.S federal statutory rates
(in thousands)   December 31,
2021
    December 31,
2020
 
                         
Federal statutory income taxes   $ (5,202 )     (21.0 )%   $ (4,665 )     (21.0 )%
State income taxes     (373 )     (1.5 )%     56       0.3 %
Deferred true-up     562       2.3 %     (64 )     (0.3 )%
Research and development/orphan drug tax credit     (1,898 )     (7.7 )%     (1,766 )     (8.0 )%
Other     486       2.0 %     202       0.9 %
Change in valuation allowance     6,425       25.9 %     6,237       28.1 %
Provision for income tax   $
-
     
-
    $
-
     
-